The European Society for Medical Oncology (ESMO) holds its annual primary meeting to provide an opportunity for researchers from across the world to come together to discuss the latest, exciting advances in cancer treatment. This year, the ESMO Congress took place in Madrid, Spain from October 23 to October 27, 2026.
While most multiple myeloma research is presented at hematology meetings, such as the American Society of Hematology (ASH) Annual Meeting, rather than at ESMO, which focuses mainly on solid tumors, ESMO 2026 brought a promising update in multiple myeloma.
See below for a guide on the latest multiple myeloma news you should know:
Presented at ESMO 2026
A new bispecific antibody shows lasting responses in heavily pretreated myeloma
Bispecific antibodies are drugs that connect a person’s own immune cells (T cells) to myeloma cells so the immune system can attack them. LBL-034 is an investigational bispecific antibody from Leads Biolabs that targets a protein on myeloma cells called GPRC5D, the same target as the approved drug talquetamab (Talvey). In an early study presented at ESMO, 56 people with relapsed or refractory multiple myeloma received LBL-034. They had received a median of 4.5 earlier treatments, and many had high-risk features.
Among the 41 people who received the most effective doses, the median time before their myeloma grew was 21.8 months. LBL-034 also worked in people whose myeloma had grown after earlier BCMA-targeted treatments such as CAR-T therapy, with 85.7% of them responding. Side effects were mostly mild, including cytokine release syndrome (CRS), an immune reaction that is common with this type of treatment.
Why it matters: People whose myeloma has come back after many treatments, including BCMA-targeted therapies, need new options. These results are early and come from a small study without a comparison group, and the details were shared in a company press release. A larger phase 3 trial is being prepared. LBL-034 is not yet approved.
Other just-announced multiple myeloma news
Elranatamab (Elrexfio) outperforms standard treatments as early as first relapse
Elranatamab is a bispecific antibody that targets BCMA, a protein found on myeloma cells. It’s currently FDA-approved for people who have already had at least 4 prior lines of treatment. On October 27, Pfizer announced results from the phase 3 MagnetisMM-32 trial, which tested elranatamab much earlier in care. The trial included 523 people in 26 countries whose myeloma had come back after 1 to 4 prior treatments that included lenalidomide (Revlimid) and an anti-CD38 antibody such as daratumumab (Darzalex).
Elranatamab on its own was compared with the doctor’s choice of 3 standard treatment combinations. People on elranatamab had a significantly lower risk of their myeloma growing or death. At 18 months, an estimated 68% of people on elranatamab were alive without their myeloma growing. Serious infections were more common with elranatamab (27.5% vs 18.1%).
Why it matters: Many people now receive lenalidomide and daratumumab as part of their first treatment, so options for when myeloma comes back are increasingly important. These results could allow elranatamab to be used much earlier. Full results, including whether elranatamab helps people live longer, have not yet been shared. Pfizer plans to submit the data to regulators.
AbbVie asks the FDA to approve etentamig, another BCMA bispecific antibody
Etentamig is an investigational, second-generation bispecific antibody that targets BCMA and is given intravenously. On October 27, AbbVie submitted it to the FDA for approval in relapsed or refractory multiple myeloma. The application is based on the phase 3 CERVINO trial, presented at the International Myeloma Society meeting in September. The trial compared etentamig with standard treatments in people who had received at least 2 prior lines of therapy, including the 3 main classes of myeloma drugs.
Etentamig significantly lengthened the time before myeloma grew compared with standard treatments, and the benefit was seen across all patient subgroups studied. Fewer people stopped etentamig because of side effects (3.6% vs 14%).
Why it matters: Bispecific antibodies are becoming a key part of myeloma care, and more options may make it easier to find a treatment that fits each person. AbbVie says it aims to make etentamig an option for people wherever they receive care. The FDA will now review the application.
Teclistamab (Tecvayli) on its own is approved in Europe as early as first relapse
Teclistamab is a bispecific antibody that targets BCMA. On October 23, the European Commission approved teclistamab on its own for adults whose myeloma has come back after at least 1 prior treatment. This follows its European approval in August 2026 in combination with daratumumab for the same group of patients.
The approval is based on the phase 3 MajesTEC-9 trial, which compared teclistamab with standard treatment combinations in people who had received 1 to 3 prior treatments, including lenalidomide and an anti-CD38 antibody. Teclistamab helped people live longer and go longer without their myeloma growing. Far more people on teclistamab had a complete response, meaning no myeloma could be detected on standard tests (65.9% vs 16.8%). Serious infections were more common with teclistamab (41.6% vs 29.0%).
Why it matters: This is a European approval. Teclistamab on its own is not approved in the U.S. for use this early. In the U.S., teclistamab is approved on its own for people who have had at least 4 prior treatments, and in combination with daratumumab for people whose myeloma has come back after at least 1 prior treatment. If you live in the U.S., ask your care team which teclistamab options are available to you.
Multiple myeloma treatment is changing quickly, with bispecific antibodies and CAR-T therapies moving into earlier stages of care. If your myeloma has come back, ask your care team whether newer options such as bispecific antibodies, CAR-T therapy or a clinical trial might be right for you, and how to lower your risk of infection during these treatments.
Look out for more myeloma research at the ASH Annual Meeting in December 2026. To stay up to date on the latest multiple myeloma research and find clinical trials that may match your diagnosis, download the Outcomes4Me app.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.